Disclosures for "Supervised Insole Gait Analysis in MS Clinical Practice: A Cost-effective Alternative"
-
Dr. Mavor has stock in Celestra Health Systems. Dr. Mavor has received research support from the Government of Canada. Dr. Mavor has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Chan has nothing to disclose.
-
Dr. Akhavanfar has stock in Shopify. Dr. Akhavanfar has stock in Nvidia.
-
Mrs. Stölzer-Hutsch has nothing to disclose.
-
Mrs. Trentzsch has nothing to disclose.
-
Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
-
Dr. Graham has stock in Celestra Health Systems. The institution of Dr. Graham has received research support from Government of Canada. The institution of Dr. Graham has received research support from Government of Ontario. The institution of Dr. Graham has received research support from MITACS. The institution of Dr. Graham has received research support from Ontario Centre for Innovation. Dr. Graham has received intellectual property interests from a discovery or technology relating to health care.